Your browser version may not work well with NCBI's Web applications. More information here...
1: Hematology Am Soc Hematol Educ Program. 2006:205-10.Click here to read Links

Clinical issues in the management of patients with myelodysplasia.

Schiffer CA.

Barbara Ann Karmanos Cancer Institute, Wayne State University (SOM), 4100 John R. Street, 4HW-CRC, Detroit MI 48201, USA. schiffer@karmanos.org

The management of patients with myelodysplasia (MDS) can be quite complex and varies according to both the clinical manifestations in individual patients as well as complicating medical conditions. Allogeneic stem cell transplantation is the only curative treatment, but because of the older age of the patient population must be applied selectively, particularly in those with lower risk MDS as well as in patients whose clinical course is more frankly "preleukemic." Issues pertinent to the use of 5-azacytidine, decitabine and lenalidomide in patients with both higher and lower International Prognostic Staging System (IPSS) stage disease are discussed.

PMID: 17124062 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Lenalidomide (Revlimid®) Lenalidomide is used to treat a certain type of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells). Lenalidom...
    » read more ...